Brought to you by 
Galen gets exclusive US rights to Nuvo’s Synera transdermal patch
26 Jul 2013
Executive Summary
Zars Pharma Inc., part of Nuvo Research Inc. (topical pain products and a Phase II compound for immune-related diseases), has licensed Galen US Inc. (the US division of UK-based Galen Ltd.) exclusive US marketing rights to its Synera (lidocaine and tetracaine) transdermal patch, indicated for local dermal analgesia during superficial venous access and superficial dermatological procedures, including excision, electrodessication, and shave biopsy of skin lesions.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galen gets exclusive US rights to Nuvo’s Synera transdermal patch
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice